HRP20110698T1 - Kompleks nukleinske kiseline i pripravak za oslobađanje nukleinske kiseline - Google Patents

Kompleks nukleinske kiseline i pripravak za oslobađanje nukleinske kiseline Download PDF

Info

Publication number
HRP20110698T1
HRP20110698T1 HR20110698T HRP20110698T HRP20110698T1 HR P20110698 T1 HRP20110698 T1 HR P20110698T1 HR 20110698 T HR20110698 T HR 20110698T HR P20110698 T HRP20110698 T HR P20110698T HR P20110698 T1 HRP20110698 T1 HR P20110698T1
Authority
HR
Croatia
Prior art keywords
nucleic acid
release
preparation
carrier
branched cyclic
Prior art date
Application number
HR20110698T
Other languages
English (en)
Croatian (hr)
Inventor
Takeuchi Hirofumi
Tozuka Yuichi
Hira Yasuyuki
Toyobuku Hidekazu
Original Assignee
Otsuka Pharmaceutical Co.
Takeuchi Hirofumi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co., Takeuchi Hirofumi filed Critical Otsuka Pharmaceutical Co.
Publication of HRP20110698T1 publication Critical patent/HRP20110698T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
HR20110698T 2007-11-08 2008-11-06 Kompleks nukleinske kiseline i pripravak za oslobađanje nukleinske kiseline HRP20110698T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007291317 2007-11-08
PCT/JP2008/070642 WO2009061003A2 (en) 2007-11-08 2008-11-06 Nucleic acid complex and nucleic acid delivery composition

Publications (1)

Publication Number Publication Date
HRP20110698T1 true HRP20110698T1 (hr) 2011-10-31

Family

ID=40303461

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110698T HRP20110698T1 (hr) 2007-11-08 2008-11-06 Kompleks nukleinske kiseline i pripravak za oslobađanje nukleinske kiseline

Country Status (27)

Country Link
US (1) US8338584B2 (de)
EP (1) EP2217208B1 (de)
JP (1) JP5340282B2 (de)
KR (1) KR101567108B1 (de)
CN (1) CN101854918B (de)
AR (1) AR069224A1 (de)
AT (1) ATE522201T1 (de)
AU (1) AU2008325504B2 (de)
BR (1) BRPI0819187A2 (de)
CA (1) CA2704236C (de)
CO (1) CO6280469A2 (de)
CY (1) CY1112029T1 (de)
DK (1) DK2217208T3 (de)
ES (1) ES2369869T3 (de)
HR (1) HRP20110698T1 (de)
IL (1) IL205237A0 (de)
MX (1) MX2010005094A (de)
MY (1) MY149917A (de)
NZ (1) NZ584841A (de)
PL (1) PL2217208T3 (de)
PT (1) PT2217208E (de)
RU (1) RU2465009C2 (de)
SI (1) SI2217208T1 (de)
TW (1) TWI426922B (de)
UA (1) UA97559C2 (de)
WO (1) WO2009061003A2 (de)
ZA (1) ZA201002845B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428135B (zh) 2007-03-26 2014-03-01 Hirofumi Takeuchi And a carrier composition for quick-acting nucleic acid delivery
AR083445A1 (es) 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
ES2605990T3 (es) * 2010-12-29 2017-03-17 F. Hoffmann-La Roche Ag Conjugados de molécula pequeña para la administración intracelular de ácidos nucleicos
RS58985B1 (sr) * 2012-03-15 2019-08-30 Acraf Katjonski polimeri na bazi glikogena
JPWO2019131727A1 (ja) * 2017-12-27 2021-02-12 コニカミノルタ株式会社 医薬の評価方法
WO2025029927A1 (en) * 2023-07-31 2025-02-06 The Board Of Regents Of The University Of Texas System Lipid nanoparticle

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01238537A (ja) * 1988-03-18 1989-09-22 Toyo Jozo Co Ltd 肝障害治療剤
JP3150266B2 (ja) * 1994-04-01 2001-03-26 江崎グリコ株式会社 環状構造を有するグルカンおよびその製造方法
US6248566B1 (en) 1994-09-13 2001-06-19 Ezaki Glico Co., Ltd. Glucan having cyclic structure and method for producing the same
JP3107358B2 (ja) 1994-09-13 2000-11-06 江崎グリコ株式会社 環状構造を有するグルカンおよびその製造方法
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5827697A (en) * 1995-03-31 1998-10-27 Ezaki Glico Co., Ltd. Process for preparing glucans having a cyclic structure
US20030092180A1 (en) 2001-08-27 2003-05-15 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
JPH11292795A (ja) 1998-04-02 1999-10-26 Yamanouchi Pharmaceut Co Ltd Hivコファクター抑制剤
EP1829856A3 (de) 1998-11-12 2009-02-25 Invitrogen Corporation Transfektionsreagenzien
AU2002368202B2 (en) * 2001-11-02 2008-06-05 Insert Therapeutics, Inc Methods and compositions for therapeutic use of RNA interference
RU2289585C2 (ru) * 2002-02-04 2006-12-20 Корикса Корпорейшн Новые аминоалкилглюкозаминидфосфатные соединения, иммуностимулирующая фармацевтическая композиция, их содержащая, и способ индуцирования иммунного ответа
WO2004042002A2 (en) * 2002-08-05 2004-05-21 University Of Massachusetts Compounds for modulating rna interference
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
WO2006097725A2 (en) * 2005-03-15 2006-09-21 Queen Mary & Westfield College Pharmaceutical compositions comprising microparticles for delivery into neurons

Also Published As

Publication number Publication date
ZA201002845B (en) 2011-07-27
EP2217208B1 (de) 2011-08-31
JP2011504457A (ja) 2011-02-10
CA2704236C (en) 2015-09-15
US8338584B2 (en) 2012-12-25
EP2217208A2 (de) 2010-08-18
WO2009061003A2 (en) 2009-05-14
SI2217208T1 (sl) 2011-11-30
TWI426922B (zh) 2014-02-21
IL205237A0 (en) 2010-11-30
MX2010005094A (es) 2010-05-27
CN101854918A (zh) 2010-10-06
RU2010123168A (ru) 2011-12-20
UA97559C2 (uk) 2012-02-27
DK2217208T3 (da) 2011-10-10
ES2369869T3 (es) 2011-12-07
CN101854918B (zh) 2012-11-28
CA2704236A1 (en) 2009-05-14
KR20100092007A (ko) 2010-08-19
RU2465009C2 (ru) 2012-10-27
CO6280469A2 (es) 2011-05-20
US20100305190A1 (en) 2010-12-02
AU2008325504B2 (en) 2013-03-07
ATE522201T1 (de) 2011-09-15
KR101567108B1 (ko) 2015-11-06
PL2217208T3 (pl) 2012-01-31
TW200927175A (en) 2009-07-01
BRPI0819187A2 (pt) 2015-05-05
AU2008325504A1 (en) 2009-05-14
WO2009061003A3 (en) 2010-05-27
PT2217208E (pt) 2011-11-08
CY1112029T1 (el) 2015-11-04
JP5340282B2 (ja) 2013-11-13
MY149917A (en) 2013-10-31
NZ584841A (en) 2011-12-22
HK1142278A1 (en) 2010-12-03
AR069224A1 (es) 2010-01-06

Similar Documents

Publication Publication Date Title
BR0108080A (pt) Preparação de formas de dosagem de solução clara aquosa com ácidos biliares
Mao et al. Chitosan-based formulations for delivery of DNA and siRNA
HRP20190878T1 (hr) Modificirane aminokiseline koje sadrže azidnu grupu
BR112014010050A8 (pt) derivados de aminoácido funcionalizados na terminação n capazes de formar microesferas de encapsulação de fármaco
JP2011057686A5 (de)
BR9912395A (pt) Preparação de formas de dosagem de solução clara aquosa com ácidos biliares
WO2009095479A3 (en) Prodrug comprising a self-cleavable linker
MX2012002502A (es) Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos.
BR112013016772B8 (pt) compostos, uso do composto e composição farmacêutica
WO2011079279A3 (en) Nanoconjugates and nanoconjugate formulations
TR201900778T4 (tr) İmmünojenik bileşim.
EP2537533A3 (de) Mittels indirekter chemischer Konjugation erhaltene Antitumor-Biokonjugate von Hyaluronsäure oder Derivaten davon
TR200806298A2 (tr) Farmasötik formülasyon
PH12013500477A1 (en) Aqueous drug delivery system comprising off-flavor masking agent
MX2011010547A (es) Composiciones farmaceuticas estables de diclofenaco.
RU2010123168A (ru) Комплекс нуклеиновой кислоты и композиция для доставки нуклеиновой кислоты
WO2008141107A8 (en) Compositions that include a hydrophobic compound and a polyamino acid conjugate
JP2015502971A5 (de)
CN108635590B (zh) 一种pH响应的多糖–硼替佐米纳米球及其制备方法和应用
ATE485261T1 (de) Salicylsäurederivate
JP2011504457A5 (de)
WO2010024557A3 (en) Biopolymer conjugates comprising an interleukin-11 analog
BR112013004275A2 (pt) glicodendrímeros de polipropileterimina
BRPI0403909A (pt) Solução aquosa de tensoativos anfotéricos altamente concentrada
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.